Literature DB >> 2554494

p53: a frequent target for genetic abnormalities in lung cancer.

T Takahashi1, M M Nau, I Chiba, M J Birrer, R K Rosenberg, M Vinocour, M Levitt, H Pass, A F Gazdar, J D Minna.   

Abstract

Allele loss is a hallmark of chromosome regions harboring recessive oncogenes. Lung cancer frequently demonstrates loss of heterozygosity on 17p. Recent evidence suggests that the p53 gene located on 17p13 has many features of such an antioncogene. The p53 gene was frequently mutated or inactivated in all types of human lung cancer. The genetic abnormalities of p53 include gross changes such as homozygous deletions and abnormally sized messenger RNAs along with a variety of point or small mutations, which map to the p53 open reading frame and change amino acid sequence in a region highly conserved between mouse and man. In addition, very low or absent expression of p53 messenger RNA in lung cancer cell lines compared to normal lung was seen. These findings, coupled with the previous demonstration of 17p allele loss in lung cancer, strongly implicate p53 as an anti-oncogene whose disruption is involved in the pathogenesis of human lung cancer.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2554494     DOI: 10.1126/science.2554494

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  297 in total

1.  Alternatively spliced products CC3 and TC3 have opposing effects on apoptosis.

Authors:  S Whitman; X Wang; R Shalaby; E Shtivelman
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

Review 2.  Molecular genetic abnormalities in the pathogenesis of human lung cancer.

Authors:  E Forgacs; S Zöchbauer-Müller; E Oláh; J D Minna
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

Review 3.  Lung cancer therapeutics that target signaling pathways: an update.

Authors:  M Roshni Ray; David Jablons; Biao He
Journal:  Expert Rev Respir Med       Date:  2010-10       Impact factor: 3.772

4.  Low Frequency Loss of Heterozygosity in the BRCA1 Region in Japanese Sporadic Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1996-12-20       Impact factor: 4.239

5.  p53 functions as a cell cycle control protein in osteosarcomas.

Authors:  L Diller; J Kassel; C E Nelson; M A Gryka; G Litwak; M Gebhardt; B Bressac; M Ozturk; S J Baker; B Vogelstein
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

6.  Hypophosphorylation of Mdm2 augments p53 stability.

Authors:  Christine Blattner; Trevor Hay; David W Meek; David P Lane
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

Review 7.  Molecular genetics of neurological tumours.

Authors:  R Y Chung; B R Seizinger
Journal:  J Med Genet       Date:  1992-06       Impact factor: 6.318

8.  Complex intrachromosomal rearrangement in the process of amplification of the L-myc gene in small-cell lung cancer.

Authors:  Y Sekido; T Takahashi; T P Mäkelä; Y Obata; R Ueda; T Hida; K Hibi; K Shimokata; K Alitalo; T Takahashi
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

Review 9.  Lung cancer. 9: Molecular biology of lung cancer: clinical implications.

Authors:  K M Fong; Y Sekido; A F Gazdar; J D Minna
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

10.  Mouse p53 represses the rat brain creatine kinase gene but activates the rat muscle creatine kinase gene.

Authors:  J Zhao; F I Schmieg; D T Simmons; G R Molloy
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.